Elsevier
  Sign Up Send Feedback Tell a Friend Search Archive View Sample
 
Weekly E-Mail newsletter
For physicians in Internal Medicine, Cardiology, Geriatrics, Women's Health,
and Adolescent Medicine
News from hundreds of top industry sources
It's what clinicians need to know
It's FREE!
   
  About SmartBrief

About The American Journal of Medicine, published by Elsevier

About Elsevier

Visit other Elsevier Health Science publications

Privacy Policy
   
Send AJMPlus story to a colleague.

* Your Name
* Your E-mail
* Friend's E-mail
Separate multiple addresses with commas.
  Personal Message
* Indicates required fields
Terms and Conditions: You must submit valid e-mail addresses only. Use of e-mail addresses is subject to the terms of SmartBrief's privacy policy.
Here's the story you're sending:
Removal of dabigatran by hemodialysis
Dabigatran is a newly available oral direct thrombin inhibitor approved for anticoagulation therapy. While there is no known antidote to reverse the effects of dabigatran, hemodialysis is suggested as a method of drug removal in the event of excessive anticoagulation or bleeding complications. The authors describe a case where, using serial dabigatran levels, they demonstrate effective dabigatran clearance with hemodialysis in a patient with severe intracranial hemorrhage; however, given the large volume of distribution of dabigatran, a rebound in drug level was noted.  American Journal of Kidney Diseases (3/2013)